CLINICAL TRIALS PROFILE FOR BEVIRIMAT
✉ Email this page to a colleague
Clinical Trials for Bevirimat
| Trial ID | Title | Status | Sponsor | Phase | Summary |
|---|---|---|---|---|---|
| NCT00511368 ↗ | Phase 2 Safety and Efficacy Study of Bevirimat Functional Monotherapy in HIV Treatment-Experienced Patients for 2 Weeks* | Completed | Myrexis Inc. | Phase 2 | The purpose of this study is to evaluate antiretroviral activity of up to five different oral doses administered for two weeks of bevirimat versus placebo in HIV treatment experienced patients, who have documented genotypic resistance to at least one major mutation from the IAS-USA list (2007)of resistance mutations for NRTIs, NNRTIs, or PIs. Patients will also be monitored for side effects, and the pharmacokinetics of bevirimat will be determined. |
| NCT00967187 ↗ | Safety and Efficacy Study of MPC-4326 for Treatment of Patients With HIV-1 Infection. | Completed | Myrexis Inc. | Phase 2 | To evaluate the antiretroviral activity and safety of 200 mg BID and 300 mg BID doses of MPC-4326 administered as monotherapy for 14 days to HIV-1 positive patients. Patients with an initial treatment response will have the option to continue MPC-4326 in combination with an Optimized Backround Regimen for a maximum of 72 weeks. |
| NCT01097070 ↗ | A Phase 2 Study to Assess the Pharmacokinetics of Bevirimat 100 mg Tablets Given to HIV-1 Positive Patient for 15 Days | Completed | Myrexis Inc. | Phase 2 | The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics (behavior in the body) of bevirimat administered for 15 days to HIV-positive individuals. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Summary |
Clinical Trial Conditions for Bevirimat
Condition Name
Clinical Trial Locations for Bevirimat
Trials by Country
Clinical Trial Progress for Bevirimat
Clinical Trial Phase
Clinical Trial Sponsors for Bevirimat
Sponsor Name
